Detalhe da pesquisa
1.
Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma.
Acta Haematol
; 145(4): 384-393, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-34839289
2.
Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).
Haematologica
; 102(2): 235-245, 2017 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27846613
3.
Persistence and Waning of Natural SARS-CoV-2 Antibodies Over 18 Months: Long-Term Durability of IgG Humoral Response in Healthcare Workers.
J Gen Intern Med
; 37(10): 2614-2616, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35581448
4.
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome.
Blood
; 123(12): 1864-9, 2014 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-24501214
5.
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Blood
; 124(12): 1887-93, 2014 Sep 18.
Artigo
Inglês
| MEDLINE | ID: mdl-25102853
6.
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Eur J Haematol
; 96(5): 532-40, 2016 May.
Artigo
Inglês
| MEDLINE | ID: mdl-26179864
7.
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
Acta Haematol
; 136(2): 76-84, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-27188649
8.
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Blood
; 120(13): 2581-8, 2012 Sep 27.
Artigo
Inglês
| MEDLINE | ID: mdl-22889759
9.
Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.
J Neurol
; 2024 Apr 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38630312
10.
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
Blood
; 118(17): 4547-53, 2011 Oct 27.
Artigo
Inglês
| MEDLINE | ID: mdl-21900193
11.
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Lancet Oncol
; 11(10): 934-41, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-20739218
12.
kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers.
Eur J Intern Med
; 89: 97-103, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34090748
13.
Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain.
Int J Epidemiol
; 50(2): 400-409, 2021 05 17.
Artigo
Inglês
| MEDLINE | ID: mdl-33434269
14.
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
Cancer Med
; 10(4): 1314-1326, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33492774
15.
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
PLoS One
; 16(9): e0257353, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34506616
16.
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study.
Hemasphere
; 5(3): e538, 2021 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-33604516
17.
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Ann Hematol
; 89(11): 1073-80, 2010 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-20526716
18.
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
Eur J Haematol
; 85(4): 321-8, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-20528905
19.
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Cancer Med
; 8(16): 6955-6966, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31573746
20.
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.
PLoS One
; 13(9): e0203392, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30192814